Form 4: Nkarta Director Zachary Scheiner Granted 46,000 Stock Options, Disclaims Personal Beneficial Ownership for RA Capital Funds

Nkarta, Inc. Director and 10% Owner Zachary Scheiner was granted 46,000 stock options with an exercise price of $1.83, but disclaims personal beneficial ownership as the options are held for the benefit of RA Capital funds.

Summary

• Zachary Scheiner, a Director and 10% Owner of Nkarta, Inc. (NKTX), was granted 46,000 stock options on June 5, 2025.
• The stock options have an exercise price of $1.83 per share.
• All 46,000 shares subject to the option will vest 100% on the earlier of June 5, 2026, or the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the grant date.
• The options will become fully vested upon a 'change in control' of Nkarta or upon Mr. Scheiner's separation from service due to death or 'disability'.
• Mr. Scheiner disclaims beneficial ownership of these stock options and the underlying common stock, stating they are held for the benefit of the RA Capital Healthcare Fund, L.P. and the RA Capital Nexus Fund, L.P.
• He is obligated to turn over any net cash or stock received upon exercise of the options to RA Capital Management, L.P. to offset advisory fees owed by the aforementioned funds.

Sentiment

Score: 5

Explanation: The document is a routine insider transaction report (Form 4) detailing a stock option grant to a director. While the grant itself is a positive for aligning interests, the disclaimer of personal beneficial ownership makes it a neutral event from a direct personal investment perspective. There are no significant positive or negative surprises.

Positives

• The grant of stock options, even if indirectly held, aligns the director's interests with the company's long-term performance and shareholder value creation.
• The options have a long expiration date of June 4, 2035, providing a substantial window for potential value realization if Nkarta's stock price appreciates.

Negatives

• Zachary Scheiner disclaims direct personal beneficial ownership of the options, indicating they do not represent a personal equity investment by him in Nkarta in the traditional sense, but rather an arrangement for the benefit of RA Capital funds.

Risks

• The value of the stock options is contingent on Nkarta's common stock price exceeding the exercise price of $1.83 per share.
• The disclaimer of beneficial ownership means the director's personal financial stake is not directly tied to these specific options, which could be perceived differently than a direct personal investment by an insider.

Future Outlook

The stock options are subject to a vesting schedule, with full vesting expected by June 5, 2026, or earlier under specific conditions such as a change in control, indicating a future milestone for the equity award.

Industry Context

This Form 4 filing is a routine disclosure for a director of a publicly traded biotechnology company, Nkarta, Inc., reporting the grant of stock options. Such equity grants are a common practice in the biotechnology sector to incentivize and align the interests of directors and executives with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants to directors are a standard component of compensation packages in the biotechnology and pharmaceutical industries, designed to align director incentives with shareholder value creation.
• The vesting schedule (100% on the earlier of a specific date or the next annual meeting) and the 10-year expiration period are typical for such equity awards in the industry.
• The arrangement where a director associated with an investment firm holds options for the benefit of the firm's funds is also a common practice, particularly for directors representing significant institutional investors.

Corporate Governance

Related Party Transactions

• Zachary Scheiner, a Director of Nkarta, Inc., holds the granted stock options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., and is obligated to turn over proceeds to RA Capital Management, L.P. to offset advisory fees. This constitutes a related party transaction given his association with both the issuer and RA Capital.

Stakeholder Impact

• **Shareholders:** The grant of options, even if indirectly held, can be viewed as a mechanism to align the director's interests with long-term shareholder value. The disclaimer clarifies that the direct financial benefit from these specific options accrues to the RA Capital funds, not personally to Mr. Scheiner.
• **RA Capital Funds:** The RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P. are the ultimate beneficiaries of the stock options, which could potentially enhance their returns from their investment in Nkarta.

Next Steps

• Vesting of the 46,000 stock options on the earlier of June 5, 2026, or the day preceding the first annual meeting of stockholders after the grant date.
• Potential exercise of the stock options by RA Capital Management, L.P. on behalf of its funds, subject to vesting and market conditions.

Key Dates

Keywords

Nkarta, NKTX, Form 4, Insider Transaction, Stock Option, Beneficial Ownership, RA Capital Management, Director Compensation, Equity Grant